Innovative Approach to MV Purification

The study, titled "Highly Pure Measles Virus Generated by Combination of Salt-Active Nuclease Treatment and Heparin Affinity Chromatography," by Mayer et al. addresses the challenges of purifying fragile, enveloped viruses like MV. Traditional methods often involve multiple steps, risking viral loss and reduced yields. By combining M-SAN HQ nuclease treatment with heparin affinity chromatography, researchers achieved a simplified workflow that enhances both purity and recovery rates.

Key Findings

• Enhanced Purity: The integrated approach effectively removes host-cell DNA and proteins, resulting in highly pure MV preparations.
• Increased Yield: The streamlined process minimizes viral loss, leading to higher recovery rates compared to conventional methods.
• Workflow Simplification: The combination reduces the number of purification steps, decreasing processing time and complexity.

Why This Matters

In the development of vaccines, gene therapies, and oncolytic treatments, manufacturers know that ensuring product purity is critical to meeting stringent regulatory standards and safeguarding patient safety. Host cell DNA contamination, a common challenge in viral vector production, must be reduced to levels below the FDA threshold of 10 ng/dose to ensure compliance and therapeutic efficacy. Traditional nucleases, included in the study, struggle to consistently meet these standards without adding complexity and cost, e.g. additional filtration, to the purification process.

M-SAN HQ nuclease addresses this challenge head-on, achieving DNA clearance far below the 10 ng/dose while also maintaining exceptionally high recovery of virus particles. This unique combination of performance and efficiency enables manufacturers to streamline their workflows, reduce the need for additional purification steps, and improve overall production yields.

For patients, this means faster access to safe, effective therapies; for manufacturers, it translates into lower costs, greater reliability, and confidence in meeting regulatory expectations. M-SAN HQ is paving the way for more robust, scalable, and accessible solutions in biopharmaceutical production.

"M-SAN HQ keeps us a step ahead by delivering the ideal balance of high purity and high yield, giving CDMOs, pharma and biotech companies the efficiency and reliability they need to succeed." said ArcticZymes CEO, Michael Akoh.

Ask any questions regarding the publication in this custom GPT and learn more about the new publication here.

ArcticZymes Technologies ASA 
CEO, Michael B. Akoh | Tel: +46 (0) 70 262 37 15 
CFO, Børge Sørvoll | Tel: +47 95 29 01 87 
ir@arcticzymes.com 

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in enzyme technologies, developing innovative solutions that enhance the efficiency of bioprocessing and support the creation of cutting-edge therapeutics. From optimizing biomanufacturing workflows to ensuring regulatory compliance, ArcticZymes enzymes, including SAN HQ and M-SAN HQ, are transforming the landscape of gene therapy and viral vector production. 

For more information, please contact: